ecrin-mdr-crcClinical2006Advanced colorectal cancerAdvanced Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2417225New Zealand5Capecitabine (Xeloda)bevacizumab (Avastin)oxaliplatin (Eloxatin)ECRIN MDRCompletedfalseA multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancerStudy hypothesis: Bi-monthly dose intensified capecitabine (Xeloda) and oxaliplatin (Eloxatin) with concurrent bevacizumab (Avastin) will be a tolerable, effective, drug combination in the treatment of advanced colorectal cancer. Primary outcome(s): Progression free survival2006-05-152417225ISRCTN41540878